Ionis Pharmaceuticals, Inc.
Modified Compounds and Uses Thereof

Last updated:

Abstract:

The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Status:
Application
Type:

Utility

Filling date:

10 Feb 2021

Issue date:

26 Aug 2021